Effect of Intravenous Lidocaine, Used to Attenuate Pain With Propofol Injection, on Defibrillation Threshold Testing

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Pain

In brief

The use of lidocaine, as an anesthetic drug, during implantation of an implantable cardioverter-defibrillator(ICD)will not result in a clinically significant alteration of the defibrillation threshold during ICD placement.

Key facts

Study ID

NCT03117166

Run by

Drexel University College of Medicine

People needed

19

Starts

2010-01-01

Expected to finish

2010-05-01

Last updated by the study team

2017-05-09

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any person referred to the Hahnemann University Hospital Electrophysiology Laboratory for a clinically indicated ICD implant

You may not qualify if…

• Any person under the age of 18 years
• Inability to give an informed consent
• Allergy to lidocaine
• Receiving lidocaine treatment for pain or arrhythmia
• Contraindication for DFT testing
• Not consenting for DFT testing
• Receiving energy other than 10-12.5 joules as initial DFT test
• Implant of ICD on the right side
• DFT not planned to be performed during ICD implant
• Epicardial placement of ICD leads
• Use of single coil ICD lead
• Subpectoral ICD implantation
• Cephalic cutdown used for central venous access
• Require more than 3mg/kg of 1% SQ lidocaine for local anesthesia
• Pregnant women or prisoners

Where it is running

• Hahnemann University Hospital — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.